# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Underweight.
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and raises the price target ...
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profileNo convulsions observed...